Drug Pipeline

Nadofaragene Firadenovec Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
3
Phase 3
3
Top Sponsors
Active Studies by Phase
Phase 3
3
Phase 2
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06929286 A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer… Non-Muscle Invasive Bladder Cancer Recruiting
NCT06510374 Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk… Intermediate Risk Non-Muscle Invasive Bladder Cancer Recruiting
NCT06545955 A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With… Non-muscle Invasive Bladder Cancer With Carcinoma in Situ Recruiting
Phase 2
NCT07332351 Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and… Muscle Invasive Bladder Urothelial Carcinoma Not Yet Recruiting
Phase 1/2
NCT06668493 Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis Low-grade Upper Tract Urothelial Carcinoma Recruiting
Sponsors Running Nadofaragene Firadenovec Trials
Ferring Pharmaceuticals (3) Memorial Sloan Kettering Cancer Center (1) University of Washington (1)
Disease Areas
Bladder Cancer (5)
Get alerts when Nadofaragene Firadenovec trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free